| 14.255 -0.025 (-0.18%) | 12-05 10:01 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17 | 1-year : | 19.86 |
| Resists | First : | 14.56 | Second : | 17 |
| Pivot price | 14.27  |
|||
| Supports | First : | 13.81 |
Second : | 13.35 |
| MAs | MA(5) : | 14.31  |
MA(20) : | 14.19 |
| MA(100) : | 14.46 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 56.9 |
D(3) : | 63.5 |
| RSI | RSI(14): 52.2 |
|||
| 52-week | High : | 15.68 | Low : | 12.8 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TAK ] has closed above bottom band by 44.8%. Bollinger Bands are 46.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 14.46 - 14.53 | 14.53 - 14.59 |
| Low: | 14.06 - 14.16 | 14.16 - 14.24 |
| Close: | 14.14 - 14.29 | 14.29 - 14.41 |
Thu, 04 Dec 2025
Innovent Biologics, Takeda (NYSE: TAK) seal IO, ADC pact worth up to $11.4 billion - Stock Titan
Thu, 04 Dec 2025
Capital Fund Management S.A. Raises Stake in Takeda Pharmaceutical Co. $TAK - MarketBeat
Tue, 02 Dec 2025
Brandes Investment Partners LP Boosts Stake in Takeda Pharmaceutical Co. $TAK - MarketBeat
Fri, 28 Nov 2025
Takeda Advances Late-Stage Pipeline with Positive Phase 3 Data - TipRanks
Thu, 30 Oct 2025
Takeda Lowers 2025 Outlook After Weak Q2 And Pipeline Impairment Charges - Sahm
Tue, 21 Oct 2025
Takeda Pharmaceutical Company (TAK) Signs a Research Partnership with Nabla Bio - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 3,160 (M) |
| Held by Insiders | 1.58e+009 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 9,300 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0.07 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4 |
| Profit Margin | 0.7 % |
| Operating Margin | 15.2 % |
| Return on Assets (ttm) | 2 % |
| Return on Equity (ttm) | 0.4 % |
| Qtrly Rev. Growth | -5.5 % |
| Gross Profit (p.s.) | 95.33 |
| Sales Per Share | 147.33 |
| EBITDA (p.s.) | 38 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 203.57 |
| PEG Ratio | 0 |
| Price to Book value | 3.56 |
| Price to Sales | 0.09 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 1.064e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|